Trends of Rifampicin Resistance in Patients with Pulmonary Tuberculosis: A Longitudinal Analysis Based on Drug Resistance Screening in Eastern China Between 2015 and 2019

References

• World Health Organization. Global tuberculosis report 2021; 2021. Available from: https://apps.who.int/iris/handle/10665/346387. Accessed December 20, 2022.
   Google Scholar
• Yang C, Luo T, Shen X, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. Lancet Infect Dis. 2017;17(3):275–284. doi:10.1016/S1473-3099(16)30418-2
   PubMed Web of Science ®Google Scholar
• Murase LS, Perez de Souza JV, Meneguello JE, et al. Possible binding of piperine in Mycobacterium tuberculosis RNA polymerase and rifampin synergism. Antimicrob Agents Chemother. 2019;63(11):1. doi:10.1128/AAC.02520-18
   Web of Science ®Google Scholar
• Chen L, Fu X, Tian P, et al. Upward trends in new, rifampicin-resistant and concurrent extrapulmonary tuberculosis cases in northern Guizhou Province of China. Sci Rep. 2021;11(1):18023. doi:10.1038/s41598-021-97595-8
   Web of Science ®Google Scholar
• Song W-M, Li Y-F, Ma X-B, et al. Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018. Respir Res. 2019;20(1):223. doi:10.1186/s12931-019-1199-3
   Web of Science ®Google Scholar
• Du L, Zhang Y, Lv X, et al. Prevalence of multidrug-resistant tuberculosis in Dalian, China: a retrospective study. Infect Drug Resist. 2021;14:1037–1047. doi:10.2147/IDR.S294611
   PubMed Web of Science ®Google Scholar
• Micheni LN, Kassaza K, Kinyi H, et al. Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda. PLoS One. 2021;16(10):e0259221. doi:10.1371/journal.pone.0259221
   Web of Science ®Google Scholar
• Diriba G, Kebede A, Tola HH, et al. Surveillance of drug resistance tuberculosis based on reference laboratory data in Ethiopia. Infect Dis Poverty. 2019;8(1):54. doi:10.1186/s40249-019-0554-4
   Web of Science ®Google Scholar
• Liu Z, Zhang M, Wang J, et al. Longitudinal analysis of prevalence and risk factors of rifampicin-resistant tuberculosis in Zhejiang, China. Biomed Res Int. 2020;2020:3159482. doi:10.1155/2020/3159482
   Web of Science ®Google Scholar
• Songhua C, Wu BB, Liu ZW, et al. An analysis on the epidemic characteristics of tuberculosis drug resistance in Zhejiang Province. Prev Med. 2016;28(8):757–761+765.
   Google Scholar
• China national Bureau of statistics. 2020 China statistical yearbook; 2021. Available from: http://www.stats.gov.cn/tjsj/ndsj/2020/indexch.htm. Accessed December 20, 2022.
   Google Scholar
• Jiang W, Peng Y, Wang X, et al. Policy changes and the screening, diagnosis and treatment of drug-resistant tuberculosis patients from 2015 to 2018 in Zhejiang Province, China: a retrospective cohort study. BMJ Open. 2021;11(4):e047023. doi:10.1136/bmjopen-2020-047023
   Web of Science ®Google Scholar
• Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38(3):516–528. doi:10.1183/09031936.00073611
   PubMed Web of Science ®Google Scholar
• Ioannidis P, Papaventsis D, Karabela S, et al. Cepheid GeneXpert MTB/RIF assay for Mycobacterium tuberculosis detection and rifampin resistance identification in patients with substantial clinical indications of tuberculosis and smear-negative microscopy results. J Clin Microbiol. 2011;49(8):3068–3070. doi:10.1128/JCM.00718-11
   PubMed Web of Science ®Google Scholar
• Albert H, Nathavitharana RR, Isaacs C, et al. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J. 2016;48(2):516–525. doi:10.1183/13993003.00543-2016
   PubMed Web of Science ®Google Scholar
• Cuiyu L, Suping L, Baoshan P, et al. Drug resistance in pulmonary tuberculosis patients in Jiamusi City, Heilongjiang Province, 2017–2020. Dis Surveilll. 2021;36(10):1052–1056.
   Google Scholar
• Maimaitiaili A, Huang QL, Guerseman A, Renati A. Analysis of drug-resistance to rifampicin and isoniazid in 1307 patients with pulmonary tuberculosis in Kashgar, Xinjiang. Chin J Antituberculosis. 2020;42(11):1209–1213.
   Google Scholar
• Mizukoshi F, Kobayashi N, Kirikae F, et al. Molecular epidemiology of drug-resistant Mycobacterium Tuberculosis in Japan. MSphere. 2021;6(4):e0097820. doi:10.1128/mSphere.00978-20
   Web of Science ®Google Scholar
• Jain A, Singh PK, Chooramani G, et al. Drug resistance and associated genetic mutations among patients with suspected MDR-TB in Uttar Pradesh, India. Int J Tuberc Lung Dis. 2016;20(7):870–875. doi:10.5588/ijtld.15.0874
   PubMed Web of Science ®Google Scholar
• Seifert M, Aung HT, Besler N, et al. Age and sex distribution of Mycobacterium tuberculosis infection and rifampicin resistance in Myanmar as detected by Xpert MTB/RIF. BMC Infect Dis. 2021;21(1):781. doi:10.1186/s12879-021-06296-0
   Web of Science ®Google Scholar
• Liang L, Wu Q, Gao L, et al. Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax. 2012;67(7):632–638. doi:10.1136/thoraxjnl-2011-200018
   Web of Science ®Google Scholar
• Li Q, Zhao G, Wu L, et al. Prevalence and patterns of drug resistance among pulmonary tuberculosis patients in Hangzhou, China. Antimicrob Resist Infect Control. 2018;7:61. doi:10.1186/s13756-018-0348-7
   Web of Science ®Google Scholar
• Horne DJ, Kohli M, Zifodya JS, et al. Xpert MTB/RIF and Xpert MTB/RIF ultra for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2019;6(6):Cd009593. doi:10.1002/14651858.CD009593.pub4
   PubMed Web of Science ®Google Scholar
• Nasiri MJ, Zamani S, Pormohammad A, et al. The reliability of rifampicin resistance as a proxy for multidrug-resistant tuberculosis: a systematic review of studies from Iran. Eur J Clin Microbiol Infect Dis. 2018;37(1):1. doi:10.1007/s10096-017-3079-4
   Web of Science ®Google Scholar
• Vergara Gómez A, González-Martín J, García-Basteiro AL. Xpert® MTB/RIF: usefulness for the diagnosis of tuberculosis and resistance to rifampicin. Med Clin. 2017;149(9):399–405. doi:10.1016/j.medcli.2017.06.007
   Web of Science ®Google Scholar
• Steingart KR, Schiller I, Horne DJ, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;2014(1):CD009593. doi:10.1002/14651858.CD009593.pub3
   PubMed Web of Science ®Google Scholar
• Shao Y, Peng H, Chen C, et al. Evaluation of GeneXpert MTB/RIF for detection of pulmonary tuberculosis at peripheral tuberculosis clinics. Microb Pathog. 2017;105:260–263. doi:10.1016/j.micpath.2017.02.040
   Web of Science ®Google Scholar
• Cox H, Dickson-Hall L, Ndjeka N, et al. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: a retrospective cohort study. PLoS Med. 2017;14(2):e1002238. doi:10.1371/journal.pmed.1002238
   Web of Science ®Google Scholar
• World Health Organization. WHO Guidelines Approved by the Guidelines Review Committee, in WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update. World Health Organization; 2016.
   Google Scholar
• Falzon D, Schünemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017;49(3):4. doi:10.1183/13993003.02308-2016
   Web of Science ®Google Scholar
• Sulochana S, Mitchison DA, Kubendiren G, et al. Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis. J Chemother. 2009;21(2):127–134. doi:10.1179/joc.2009.21.2.127
   PubMed Web of Science ®Google Scholar
• Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010;375(9728):1830–1843. doi:10.1016/S0140-6736(10)60410-2
   PubMed Web of Science ®Google Scholar
• Marks SM, Flood J, Seaworth B, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. Emerg Infect Dis. 2014;20(5):812–821. doi:10.3201/eid2005.131037
   PubMed Web of Science ®Google Scholar
• Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis. 2003;3(7):432–442. doi:10.1016/S1473-3099(03)00671-6
   PubMed Web of Science ®Google Scholar